Publications

BibTex format

@article{Stirrup:2018:10.1186/s12981-018-0198-7,
author = {Stirrup, OT and Dunn, DT and Tostevin, A and Sabin, CA and Pozniak, A and Asboe, D and Cox, A and Orkin, C and Martin, F and Cane, P and Fairbrother, K and Fearnhill, E and Hubb, J and Porter, K and Babiker, A and Lynch, J and Hand, J and de, Souza C and Churchill, D and Perry, N and Tilbury, S and Youssef, E and Clark, D and Gazzard, B and Nelson, M and Mabika, T and Mandalia, S and Anderson, J and Munshi, S and Post, F and Adefisan, A and Taylor, C and Gleisner, Z and Ibrahim, F and Campbell, L and Chadwick, D and Baillie, K and Gilson, R and Brima, N and Williams, I and Ainsworth, J and Schwenk, A and Miller, S and Wood, C and Johnson, M and Youle, M and Lampe, F and Smith, C and Tsintas, R and Chaloner, C and Hutchinson, S and Phillips, A and Hill, T and Jose, S and Huntington, S and Thornton, A and Walsh, J and Mackie, N and Winston, A and Weber, J and Ramzan, F and Carder, M and Leen, C and Wilson, A and Morris, S and Gompels, M and Allan, S and Palfreeman, A and Lewszuk, A and K},
doi = {10.1186/s12981-018-0198-7},
journal = {AIDS Research and Therapy},
title = {Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data},
url = {http://dx.doi.org/10.1186/s12981-018-0198-7},
volume = {15},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: The prevalence of HIV-1 resistance to antiretroviral therapies (ART) has declined in high-income countries over recent years, but drug resistance remains a substantial concern in many low and middle-income countries. The Q151M and T69 insertion (T69i) resistance mutations in the viral reverse transcriptase gene can reduce susceptibility to all nucleoside/tide analogue reverse transcriptase inhibitors, motivating the present study to investigate the risk factors and outcomes associated with these mutations. Methods: We considered all data in the UK HIV Drug Resistance Database for blood samples obtained in the period 1997-2014. Where available, treatment history and patient outcomes were obtained through linkage to the UK Collaborative HIV Cohort study. A matched case-control approach was used to assess risk factors associated with the appearance of each of the mutations in ART-experienced patients, and survival analysis was used to investigate factors associated with viral suppression. A further analysis using matched controls was performed to investigate the impact of each mutation on survival. Results: A total of 180 patients with Q151M mutation and 85 with T69i mutation were identified, almost entirely from before 2006. Occurrence of both the Q151M and T69i mutations was strongly associated with cumulative period of virological failure while on ART, and for Q151M there was a particular positive association with use of stavudine and negative association with use of boosted-protease inhibitors. Subsequent viral suppression was negatively associated with viral load at sequencing for both mutations, and for Q151M we found a negative association with didanosine use but a positive association with boosted-protease inhibitor use. The results obtained in these analyses were also consistent with potentially large associations with other drugs. Analyses were inconclusive regarding associations between the mutations and mortality, but mortality was high for pati
AU  - Stirrup,OT
AU  - Dunn,DT
AU  - Tostevin,A
AU  - Sabin,CA
AU  - Pozniak,A
AU  - Asboe,D
AU  - Cox,A
AU  - Orkin,C
AU  - Martin,F
AU  - Cane,P
AU  - Fairbrother,K
AU  - Fearnhill,E
AU  - Hubb,J
AU  - Porter,K
AU  - Babiker,A
AU  - Lynch,J
AU  - Hand,J
AU  - de,Souza C
AU  - Churchill,D
AU  - Perry,N
AU  - Tilbury,S
AU  - Youssef,E
AU  - Clark,D
AU  - Gazzard,B
AU  - Nelson,M
AU  - Mabika,T
AU  - Mandalia,S
AU  - Anderson,J
AU  - Munshi,S
AU  - Post,F
AU  - Adefisan,A
AU  - Taylor,C
AU  - Gleisner,Z
AU  - Ibrahim,F
AU  - Campbell,L
AU  - Chadwick,D
AU  - Baillie,K
AU  - Gilson,R
AU  - Brima,N
AU  - Williams,I
AU  - Ainsworth,J
AU  - Schwenk,A
AU  - Miller,S
AU  - Wood,C
AU  - Johnson,M
AU  - Youle,M
AU  - Lampe,F
AU  - Smith,C
AU  - Tsintas,R
AU  - Chaloner,C
AU  - Hutchinson,S
AU  - Phillips,A
AU  - Hill,T
AU  - Jose,S
AU  - Huntington,S
AU  - Thornton,A
AU  - Walsh,J
AU  - Mackie,N
AU  - Winston,A
AU  - Weber,J
AU  - Ramzan,F
AU  - Carder,M
AU  - Leen,C
AU  - Wilson,A
AU  - Morris,S
AU  - Gompels,M
AU  - Allan,S
AU  - Palfreeman,A
AU  - Lewszuk,A
AU  - Kegg,S
AU  - Faleye,A
AU  - Ogunbiyi,V
AU  - Mitchell,S
AU  - Hay,P
AU  - Kemble,C
AU  - Russell-Sharpe,S
AU  - Gravely,J
AU  - Allan,S
AU  - Harte,A
AU  - Tariq,A
AU  - Spencer,H
AU  - Jones,R
AU  - Pritchard,J
AU  - Cumming,S
AU  - Atkinson,C
AU  - Mital,D
AU  - Edgell,V
AU  - Allen,J
AU  - Ustianowski,A
AU  - Murphy,C
AU  - Gunder,I
DO  - 10.1186/s12981-018-0198-7
PY  - 2018///
SN  - 1742-6405
TI  - Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
T2  - AIDS Research and Therapy
UR  - http://dx.doi.org/10.1186/s12981-018-0198-7
UR  - http://hdl.handle.net/10044/1/72910
VL  - 15
ER  -

Download

ProfessorJonathanWeber

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)